Email Medtest Medtest Headquarters Medtest Facebook Medtest Linkedin

MedTest Holdings Acquires Pointe Scientific

Jun 3, 2013 - press releases

Cortlandt Manor, New York – June 3, 2013 MedTest Holdings, the parent company of MedTest DX, Inc. (“MedTest”) has signed a definitive agreement to acquire Pointe Scientific, Inc. (“Pointe”) located in Canton, Michigan. Financial details of the acquisition were not disclosed. MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing. 

Pointe has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981. Pointe’s robust R&D program focuses on continual improvement of existing products and bringing new products and technologies to the marketplace. 

“We are thrilled to add the Pointe Scientific team to our family” said Hanjoon Ryu, CEO of MedTest. “Combined, MedTest and Pointe become uniquely positioned to offer a broad range of clinical chemistry products and services for clinical laboratories and physician office laboratories worldwide. Going forward, we will continue to serve our customers with the same commitment to quality and customer service that both companies have proven in the past.” 

Together, Pointe and MedTest offer a broad reagent and instrument product portfolio including testing solutions for drugs of abuse, general chemistry, immunochemistry, diabetes and cardiovascular diseases serving physician’s office laboratories, reference laboratories, hospital laboratories and commercial laboratories. 

For more information, please contact Kay Newel at or Debbie Whitehair at


PR-M2111-01   07/13

Pointe Scientific Adds an Improved Hemoglobin A1c Product to its Broad List of Chemistry Reagents

May 15, 2013 - press releases

A ready to use Hemoglobin A1c with only a single R2 component


Canton, Michigan, May 15, 2013 – Pointe Scientific has introduced the first two component immunoturbidimetric Hemoglobin A1c reagent available in the United States for the determination of Hemoglobin A1c on general chemistry analyzers.

The methodology uses Pointe Scientific’s highly specific monoclonal antibody to Hemoglobin A1c to generate increased turbidity in the presence of Hemoglobin A1c. With the single R2 component stabilized, mixing two separate R2 components is no longer necessary. This single R2 component provides the consumer with unsurpassed ease of use. Automated hemolysis can be performed on many different chemistry analyzers, providing a totally automated test system.

The simple competitive binding principle used in the Pointe Scientific Hemoglobin A1c method provides direct determination of Hemoglobin A1c. This eliminates the need to perform a total hemoglobin assay, providing greater accuracy and precision by removing the additive error from performing two assays to achieve a single result. The Pointe Scientific method can be applied to most general chemistry analyzers. This eliminates the need for a dedicated Hemoglobin A1c analyzer, reducing capital expenditures and labor costs while increasing efficiency and productivity.

These Pointe Scientific Hemoglobin A1c reagents are liquid-stable and have been shown to be accurate and precise. Pointe Scientific’s Hemoglobin A1c calibrators are referenced to IFCC materials and are also NGSP certified. Hemoglobin A1c controls are also available for use with the new Hemoglobin A1c reagent.

For more information about the new Hemoglobin A1c reagent, visit us at, or contact

PR-H7546-01   05/13

PREV 1 2 3 4 5 6 7 8 9 10